Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Corp. Affairs Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,484 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 3,587 · Balance 11,484 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. F2: Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 9,548 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 1,936 · Balance 9,548 F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
| Common StockSEC Table I · non-derivative | Direct | 8,722 |
Reported balance
After 2026-09-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-14 · Sale · Disposed 826 · Balance 8,722 F4: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
F4: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F5: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 15, 2026 21:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 826 | $157.45 | $130,050.56 |
DisclosureSEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,722 F4 · kind: The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,936 | $156.22 | $302,441.92 |
DisclosureSEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,548 F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 3,587 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000010 · wk-form4_1789506190.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,484 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. F2 · balance_after: Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| May 26, 2026 Filed May 28, 2026 22:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,888 | $156.64 | $609,023.32 |
DisclosureSEC source: 0001909817-26-000007 · wk-form4_1780006136.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,799 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 5,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 13 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,479 Underlying: Common Stock · 5,479 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock . F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 31,234 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 12 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,234 Underlying: Common Stock · 31,234 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 11 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,812 Underlying: Common Stock · 1,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock . F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 10 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,083 Underlying: Common Stock · 1,541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock . F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 5,378 | $124.12 | $667,517.36 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 8 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,581 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 9,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 7 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,959 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 978 | $124.12 | $121,389.36 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 6 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,991 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 5 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 832 | $124.12 | $103,267.84 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,158 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · derivative · entry 9 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,801 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock . F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 864 | $123.10 | $106,358.40 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,449 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000005 · wk-form4_1771368527.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestriced Stock Unit · Derivative | 2,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · derivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and vested as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,189 | $136.06 | $161,775.34 |
DisclosureSEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,713 F2 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:22 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001909817-26-000003 · wk-form4_1770160963.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 241 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · derivative · entry 8 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,624 Underlying: Common Stock · 1,541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, and will vest as to 1,541 shares on February 13, 2026, 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award. F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, and will vest as to 1,541 shares on February 13, 2026, 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · derivative · entry 7 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,623 Underlying: Common Stock · 1,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, and will vest as to 1,811 shares on February 13, 2026, and 1,812 shares on February 13, 2027, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, and will vest as to 1,811 shares on February 13, 2026, and 1,812 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 830 | $116.69 | $96,849.13 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · nonDerivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,565 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.87 to $117.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · nonDerivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 955 | $116.79 | $111,538.17 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,854 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.75. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · derivative · entry 6 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,401 Underlying: Common Stock · 6,401 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:08 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 34,153 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000059 · wk-form4_1739574484.xml · derivative · entry 5 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,153 Underlying: Common Stock · 34,153 shares Expires 2035-02-12 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 700 | $118.31 | $82,820.08 |
DisclosureSEC source: 0000914475-25-000048 · wk-form4_1739403976.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,998 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.08 to $123.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,329 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000048 · wk-form4_1739403976.xml · derivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,328 shares on February 8, 2022, vested as to 1,328 shares on February 8, 2023, vested as to 1,329 shares on February 8, 2024, and vested as to 1,329 shares on February 8, 2025, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,328 shares on February 8, 2022, vested as to 1,328 shares on February 8, 2023, vested as to 1,329 shares on February 8, 2024, and vested as to 1,329 shares on February 8, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,329 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000048 · wk-form4_1739403976.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestriced Stock Unit · Derivative | 2,096 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000023 · wk-form4_1738708967.xml · derivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,096 Underlying: Common Stock · 2,096 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and will vest as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,096 shares on January 31, 2023, vested as to 2,096 shares on January 31, 2024, vested as to 2,096 shares on January 31, 2025, and will vest as to 2,096 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,104 | $152.94 | $168,849.40 |
DisclosureSEC source: 0000914475-25-000023 · wk-form4_1738708967.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,369 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.85to $153.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,096 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000023 · wk-form4_1738708967.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 20:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,295 | $113.66 | $147,189.70 |
DisclosureSEC source: 0000914475-24-000203 · wk-form4_1728333186.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,461 | $121.88 | $421,828.06 |
DisclosureSEC source: 0000914475-24-000201 · wk-form4_1726604500.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,672 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $120.31 to $122.48. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 238 shares purchased on February 29, 2024 and August 30, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,165 Underlying: Common Stock · 6,165 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2025, February 13, 2026, February 13, 2027, and February 13, 2028. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 30,977 | $0.00 Strike: $133.84 | $0.00 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · derivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,977 Underlying: Common Stock · 30,977 shares Expires 2034-02-13 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 856 | $133.05 | $113,889.43 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,895 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:33 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 955 | $133.10 | $127,106.30 |
DisclosureSEC source: 0000914475-24-000069 · wk-form4_1708036355.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,751 F1 · kind: Sale of 955 shares of common stock issued upon vesting of 1,811 restricted stock units on February 13, 2024 to cover payroll and withholding taxes, with the balance of the shares (856) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $129.96 to $134.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 628 | $136.78 | $85,897.84 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 4 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,895 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 700 | $134.19 | $93,932.30 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 3 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,523 F3 · kind: Sale of 700 shares of common stock issued upon vesting of 1,329 restricted stock units on February 8, 2024 to cover payroll and withholding taxes, with the balance of the shares (629) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $132.64 to $136.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 216 | $141.96 | $30,663.36 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,894 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| February 06, 2024 Filed Feb 9, 2024 00:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 240 | $141.96 | $34,070.40 |
DisclosureSEC source: 0000914475-24-000051 · wk-form4_1707439596.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,110 F1 · kind: Sale of 240 shares of common stock issued upon vesting of 456 restricted stock units on February 6, 2024 to cover payroll and withholding taxes, with the balance of the shares (216) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2020. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 992 | $140.72 | $139,591.46 |
DisclosureSEC source: 0000914475-24-000024 · wk-form4_1706918866.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,894 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.75 to $142.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 00:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,104 | $140.87 | $155,523.68 |
DisclosureSEC source: 0000914475-24-000024 · wk-form4_1706918866.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,886 F1 · kind: Sale of 1,104 shares of common stock issued upon vesting of 2,096 restricted stock units on January 31, 2024 to cover payroll and withholding taxes, with the balance of the shares (992) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.66 to $142.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,437 | $112.68 | $161,921.16 |
DisclosureSEC source: 0001209191-23-052028 · doc4.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,894 F1 · kind: Sale of 1,437 shares of common stock issued upon vesting of 2,732 restricted stock units on October 2, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,295) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · balance_after: Includes an aggregate of 139 shares purchased on August 31, 2023 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,438 | $108.22 | $155,622.95 |
DisclosureSEC source: 0001209191-23-047968 · doc4.xml · nonDerivative · entry 2 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,460 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $107.23 to $108.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 20:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,295 | $106.90 | $138,435.50 |
DisclosureSEC source: 0001209191-23-047968 · doc4.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,898 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 21, 2023 Filed Aug 24, 2023 00:01 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,600 | $107.41 | $171,862.08 |
DisclosureSEC source: 0001209191-23-047132 · doc4.xml · nonDerivative · entry 1 Boyer David W. · CIK 0001909817 · Chief Corp. Affairs Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,193 F1 · kind: Sale of 1,600 shares of common stock issued upon vesting of 3,038 performance restricted stock units on August 21, 2023 to cover payroll and withholding taxes, with the balance of the shares (1,438) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · kind: The Reporting Person was previously granted performance restricted stock units that vest upon the achievement of certain milestones that occurred on August 21, 2023. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.99 to $108.42. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.